Literature DB >> 31336328

The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.

Cecilia L Bergeria1, Andrew S Huhn1, D Andrew Tompkins2, George E Bigelow1, Eric C Strain1, Kelly E Dunn3.   

Abstract

BACKGROUND: Understanding mechanisms of physiological opioid withdrawal symptoms can inform treatment strategies. This secondary analysis evaluated the association between mydriasis (dilated pupils), a commonly-assessed opioid withdrawal metric, with self- and observer-rated opioid withdrawal severity.
METHOD: Ninety-five participants with opioid physical dependence were stabilized with morphine before receiving an injection of the opioid antagonist naloxone to precipitate withdrawal. Pupil diameter, the Subjective Opiate Withdrawal Scale (SOWS), and the Clinical Opiate Withdrawal Scale (COWS) were collected at baseline and in 15-minute intervals for 120 min following naloxone administration. Pearson product-moment correlations and linear regressions characterized the relationships between pupil measurements (baseline and peak naloxone-induced) and self- and observer-rated measures of withdrawal. Repeated-measures ANOVAs tested whether self and observer-rated withdrawal severity corresponded to unique patterns in pupil changes.
RESULTS: Baseline pupil diameter significantly correlated with SOWS and COWS peak scores. Peak naloxone-induced pupil diameter significantly correlated with SOWS scores only. Peak changes in pupil from baseline did not correspond to peak changes in self- and observer-rated withdrawal scales.
CONCLUSIONS: This study suggests that pupil diameter measurements were more closely associated with acute opioid withdrawal severity than changes in pupil diameter. Prospective research examining the mechanisms underlying the relationship between pupil diameter and opioid withdrawal severity are warranted.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Morphine; Naloxone; Opioid use disorder; Opioid withdrawal; Pupil

Mesh:

Substances:

Year:  2019        PMID: 31336328      PMCID: PMC6745696          DOI: 10.1016/j.drugalcdep.2019.05.010

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  21 in total

1.  Factors affecting pupil size after dilatation: the Twin Eye Study.

Authors:  C J Hammond; H Snieder; T D Spector; C E Gilbert
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

2.  Tolerance to miotic effects of opioids.

Authors:  Joshua P Kollars; Merlin D Larson
Journal:  Anesthesiology       Date:  2005-03       Impact factor: 7.892

3.  Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Authors:  Kelly E Dunn; D Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

4.  Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal.

Authors:  P J Fudala; J H Jaffe; E M Dax; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1990-04       Impact factor: 6.875

5.  Factors associated with complicated buprenorphine inductions.

Authors:  Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2010-07

6.  Pupil responses to intravenous heroin (diamorphine) in dependent and non-dependent humans.

Authors:  K H Tress; A A El-Sobky
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

7.  Pupillometric changes during gradual opiate detoxification correlate with changes in symptoms of opiate withdrawal as measured by the Weak Opiate Withdrawal Scale.

Authors:  R B Rosse; S Johri; M Goel; F Rahman; K A Jawor; S I Deutsch
Journal:  Clin Neuropharmacol       Date:  1998 Sep-Oct       Impact factor: 1.592

8.  Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Authors:  D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2009-08-03       Impact factor: 4.492

Review 9.  Buprenorphine for the management of opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Authors:  Kelly E Dunn; Elise M Weerts; Andrew S Huhn; Jennifer R Schroeder; David Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  Addict Biol       Date:  2018-10-08       Impact factor: 4.280

View more
  1 in total

1.  A Pilot Study of Automated Pupillometry in the Treatment of Opioid Use Disorder.

Authors:  Crandall E Peeler; Merit Gorgy; Natalie Sadlak; Shaleen Sathe; Nina Tamashunas; Marissa G Fiorello; Howard Cabral; Michael K Paasche-Orlow; Zoe M Weinstein
Journal:  J Addict Med       Date:  2021 Nov-Dec 01       Impact factor: 3.702

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.